The initial and sole drug delivery system capable of prolonged local administration of a cancer medication into the bladder has been developed, demonstrating a remarkable 82 percent success rate in achieving complete response among patients without requiring reinduction. This breakthrough offers a promising new treatment option for individuals who do not respond to BCG therapy, potentially revolutionizing the approach to managing this specific category of patients.